IVF & Reproductive Health

What our IVF and reproductive health unit covers — and who it is for

Reproductive medicine is the investigation and treatment of difficulty conceiving, in both partners. Most of the work is not IVF. It is finding out why conception has not happened, treating what is treatable, and being honest about which problems assisted reproduction can solve and which it cannot. IVF is one tool in that list, used when the reason for it is clear.

At Acıbadem International the work is organised into five strands.

• Investigation of both partners — ovarian reserve, tubal patency, the uterine cavity, and a semen analysis, done together rather than in sequence, because delay is the one variable in fertility that only moves in one direction.
• Treatment short of IVF — ovulation induction, intrauterine insemination, and the surgery that restores anatomy: fibroids, polyps, adhesions, hydrosalpinx.
• IVF and ICSI — stimulated cycles, egg retrieval, laboratory fertilisation, embryo culture to blastocyst, and transfer, fresh or frozen.
• Andrology and surgical sperm retrieval — male-factor investigation, varicocele, and the retrieval procedures used when there is no sperm in the ejaculate.
• Fertility preservation — freezing eggs, sperm or embryos before treatment that will damage fertility, or before age does.

Two neighbouring specialties overlap here. Conditions of the uterus and ovaries that are not primarily fertility problems — heavy bleeding, prolapse, cervical screening, pregnancy care once it is established — belong to gynecology and obstetrics. Hormonal disorders that affect fertility indirectly, thyroid disease and diabetes among them, are managed with endocrinology.

Who is this page for? People who have been trying for a year and do not know what happens next. People holding test results — an AMH, a semen analysis, an HSG report — that nobody has explained. Couples deciding between IUI and IVF. People whose cycles have failed and who want the reasoning examined rather than repeated. And people considering treatment abroad, who need to know what is and is not legally possible in the country they are considering, because in this field that varies more than in any other.

Infertility: what the word means, and when to investigate

Infertility is defined as the failure to conceive after twelve months of regular unprotected intercourse — six months where the female partner is over thirty-five, because at that point the cost of waiting is higher than the cost of looking. It is a clinical threshold for starting an investigation, not a diagnosis and not a verdict. A substantial proportion of couples who meet it conceive without treatment.

The definition matters mainly because of what it triggers. Crossing it is the point at which investigating both partners becomes reasonable, and the single most common failure in fertility care is investigating only one of them. Roughly speaking, the causes divide into thirds: a female factor, a male factor, and a mixed or unexplained picture — and a semen analysis is quicker, cheaper and less invasive than anything done to the female partner. It goes first, or at least alongside.

Three thresholds bring an investigation forward rather than waiting out the twelve months: absent or very irregular periods, which means ovulation cannot be assumed; a known problem — previous pelvic surgery, endometriosis, chemotherapy, an undescended testis, a previous inguinal hernia repair; and age, which is not a disease but is the variable that makes every other one more urgent.

Female infertility: the four questions an investigation answers

Female infertility is not one condition, and a useful investigation is not a long list of tests. It answers four questions in order, and each has a specific test attached.

• Is she ovulating? Regular predictable cycles usually mean yes; a mid-luteal progesterone confirms it. Absent or erratic cycles point to polycystic ovary syndrome, thyroid disease, raised prolactin, low body weight or, less often, early loss of ovarian function.
• How many eggs are left? Answered by AMH and antral follicle count together, discussed under ovarian reserve. These predict the response to stimulation. They do not predict natural conception, and they are widely misread as though they did.
• Can the egg and sperm meet? Tubal patency, tested by hysterosalpingogram or its ultrasound equivalent. A blocked, damaged or fluid-filled tube changes the plan more than almost any other finding.
• Can an embryo implant? The uterine cavity, assessed by scan and, where indicated, hysteroscopy — polyps, fibroids distorting the cavity, a septum, or the adhesions described under Asherman syndrome.

Endometriosis sits across several of these and is discussed with gynecology; its effect on fertility is partly mechanical, partly inflammatory, and it is one of the conditions where the fertility plan and the pain plan can pull in different directions.

Male infertility

Male infertility contributes to roughly half of all cases and is the half most often investigated last. The first test is a semen analysis, and it is worth knowing what it does and does not tell you. It measures concentration, motility and morphology against reference values that describe populations rather than individuals — a result below the reference range does not mean conception is impossible, and a normal result does not exclude a male factor. Because production takes about three months and varies, an abnormal result is repeated before it is acted on.

What follows from an abnormal analysis is an examination and a hormone profile, because the causes are treatable to very different degrees. Obstruction, where production is normal but the sperm cannot get out. Production failure, from genetic causes, previous chemotherapy, an undescended testis or an unknown cause. A varicocele. Hormonal causes, which are among the few that respond to medical treatment. And lifestyle and drug exposures — heat, smoking, anabolic steroids, some prescribed medicines — where the effect is real but usually modest and slow to reverse.

The complete absence of sperm in the ejaculate is azoospermia and is dealt with separately, because it is the finding that most often ends a couple’s assumption that IVF is straightforwardly available to them, and because it is more often treatable than people expect.

Unexplained infertility

Unexplained infertility is the label used when ovulation is confirmed, the tubes are open, the cavity is normal and the semen analysis is adequate — and conception still has not happened. It applies to a meaningful minority of couples and it is an honest description of the limits of testing rather than a statement that nothing is wrong.

What it usually means is that the problem lies in something no routine test measures: egg quality, fertilisation itself, early embryo development, or implantation. Standard tests examine the plumbing and the hormones; they do not examine whether an egg and a sperm can make a viable embryo. That is why IVF is sometimes diagnostic as well as therapeutic in this group — the laboratory sees what no test could show, and occasionally the answer arrives in the form of eggs that do not fertilise or embryos that arrest.

The honest position on treatment is that expectant management remains reasonable for a period in younger couples, because a proportion conceive without help; that IUI with ovulation induction is a common next step; and that age compresses the room for that patience considerably. The couple who benefit least from waiting are the ones most often told to wait.

Secondary infertility

Secondary infertility is difficulty conceiving after having already had a child, and it is more common than most people realise — and more isolating, because it attracts less sympathy and more unhelpful advice. Having conceived before is reassuring about the past and says less about the present than couples assume.

The causes are the same list as primary infertility plus the things that have happened in between. Age, which has moved for both partners. A change in ovarian reserve. Tubal damage from infection or from a previous pregnancy, including caesarean or retained placenta. Adhesions inside the uterine cavity after a surgical procedure — see Asherman syndrome. Weight change, new medical conditions and new medicines. And a male factor that has appeared or worsened, which is why the semen analysis is repeated rather than assumed from the previous pregnancy.

The investigation is the same investigation. The most common mistake is a shortened one, on the grounds that fertility has already been demonstrated.

Fertility testing: what each test actually answers

Fertility tests are frequently reported without interpretation, and the result is a couple holding numbers that frighten them for the wrong reasons. This section takes the common tests one at a time and states what each one predicts — and, as importantly, what it does not.

Ovarian reserve, AMH and antral follicle count

Ovarian reserve describes how many eggs remain, and it is measured two ways that are used together. The AMH test measures anti-Müllerian hormone, produced by small developing follicles, and can be taken at any point in the cycle. The antral follicle count is an ultrasound count of the small follicles visible at the start of a cycle. They correlate, and where they disagree the discrepancy itself is informative.

Here is the point that is misunderstood more than any other in fertility medicine. These tests predict how many eggs a stimulated cycle will produce. They do not predict whether you can conceive naturally, and they do not measure egg quality. A low AMH in a woman in her early thirties means fewer eggs will be collected in an IVF cycle; it does not mean she cannot conceive this month, and women with low AMH conceive naturally all the time. Egg quality tracks with age, not with AMH — which is why a thirty-year-old with a low count and a forty-two-year-old with a normal one face very different situations despite superficially similar numbers.

What the tests genuinely change: the stimulation protocol, the dose, the expected number of eggs, and the conversation about how many cycles may be needed. What they should not do is push someone into urgent treatment on the strength of a single number, or reassure someone whose age is the real issue.

Diminished ovarian reserve and premature ovarian insufficiency

Diminished ovarian reserve means the tests indicate fewer remaining eggs than expected for the person’s age. It is a description of quantity, and the qualification in the section above applies in full: it forecasts the yield of a stimulated cycle rather than the chance of conception this cycle.

Premature ovarian insufficiency is a different and more serious finding: ovarian function declining before the age of forty, with irregular or absent periods, a raised FSH and often the symptoms of oestrogen deficiency. It is not simply an extreme of diminished reserve — it carries implications for bone and cardiovascular health that continue long after the fertility question is settled, and hormone replacement is usually part of the management, decided by the treating doctors. Causes include genetic conditions, autoimmune disease, previous chemotherapy or radiotherapy and previous ovarian surgery; in many cases none is found. Spontaneous ovulation still occurs intermittently in a proportion of women with this diagnosis, which is why it is described as insufficiency rather than failure.

Hysterosalpingogram (HSG test)

A hysterosalpingogram — the HSG test — checks whether the fallopian tubes are open and outlines the shape of the uterine cavity. Contrast is passed through the cervix while X-ray images are taken, and the contrast either spills freely from the ends of the tubes or it does not. The ultrasound equivalent, using a contrast foam rather than X-ray, answers the same question without radiation.

It is done in the first half of the cycle, after menstruation and before ovulation, so that an early pregnancy cannot be present. It is uncomfortable rather than painful for most people, briefly and in a cramping way, and the discomfort is greater when a tube is blocked because the contrast has nowhere to go.

Three findings change the plan. Both tubes open: the tubal question is answered and attention moves elsewhere. One tube blocked: often manageable, since a single functioning tube is compatible with conception. Both tubes blocked, or a tube distended with fluid: this is hydrosalpinx, it points toward IVF, and it needs dealing with before IVF rather than after. There is also a well-described and slightly odd effect worth knowing: conception rates rise modestly in the months immediately after an HSG, which is why the test is occasionally described as mildly therapeutic as well as diagnostic.

Hysteroscopy

Hysteroscopy is direct inspection of the inside of the uterus with a thin telescope passed through the cervix. Where a scan or an HSG suggests something inside the cavity, hysteroscopy is what confirms it and, in the same sitting, usually removes it.

What it finds and treats: endometrial polyps, submucosal fibroids that bulge into the cavity, a uterine septum, retained tissue after a pregnancy, and the adhesions of Asherman syndrome. What distinguishes it from other investigations is that it is both. A diagnostic hysteroscopy in the outpatient setting takes minutes and needs no general anaesthetic; an operative one, where something is being removed, is usually done under anaesthesia.

Its place in the fertility pathway is more debated than the enthusiasm around it suggests. Investigating the cavity is clearly worthwhile where the scan is abnormal, where there is a history suggesting adhesions, or where embryos of good quality have repeatedly failed to implant. Performing it routinely on everyone before a first IVF cycle, with a normal scan and no history, has not been shown to improve outcomes — and a page that presents it as a standard part of every workup is describing a business model rather than the evidence.

Semen analysis and sperm DNA fragmentation

The semen analysis is the first male test and the one that most changes what happens next. The sample is produced after a defined abstinence interval, because both a very short and a very long interval distort the result, and it is examined for volume, concentration, motility and morphology. Values are compared against reference ranges derived from men who conceived within a year — which is why they describe likelihood rather than possibility, and why a result flagged as abnormal is not a diagnosis of sterility.

Sperm DNA fragmentation testing measures breaks in the genetic material carried by the sperm, which a standard analysis does not assess. It is not a routine test. Its recognised uses are specific: recurrent pregnancy loss, repeated failure of IVF or ICSI cycles, and unexplained infertility with a normal conventional analysis. Where fragmentation is high, the contributors that can actually be addressed are oxidative — varicocele, infection, smoking, heat exposure, long abstinence intervals — and the laboratory response is to select sperm differently or to use surgically retrieved sperm, which typically shows less fragmentation than ejaculated sperm in these men.

Hydrosalpinx

Hydrosalpinx is a fallopian tube blocked at its far end and distended with fluid. The word describes exactly that: a water tube. It matters far more than its simplicity suggests, because it does two separate kinds of damage — and the second is the one people are not told about.

The first is obvious: a blocked tube cannot carry an egg. The second is that the trapped fluid does not stay in the tube. It leaks backwards into the uterine cavity, where it is toxic to embryos and mechanically washes them out of position. That is why a hydrosalpinx reduces the success of IVF as well as of natural conception — IVF bypasses the tube entirely, yet the fluid still reaches the cavity. A woman can produce good embryos, transfer them into a normal-looking uterus, and have them fail for a reason that sits in a tube nobody was using.

The consequence is one of the clearest recommendations in reproductive surgery: a hydrosalpinx visible on ultrasound should be dealt with before IVF, not after a failed cycle. Treatment is laparoscopic — either removing the affected tube, or dividing it to interrupt the connection with the uterus where removal would compromise the ovarian blood supply. Where laparoscopy is not possible, blocking the tube hysteroscopically is an alternative. Removing a damaged tube does not reduce ovarian reserve when the blood supply is preserved, which is the question people most often want answered before agreeing to it.

How it is found matters too. A small hydrosalpinx may be invisible on a routine scan and show only on HSG as a dilated tube that does not spill; a large one is visible as a sausage-shaped fluid collection on ultrasound. The usual causes are previous pelvic infection, endometriosis and previous pelvic surgery, and many women have no recollection of any of them.

Asherman syndrome

Asherman syndrome is scar tissue inside the uterine cavity, where the walls adhere to each other and the lining that should regenerate each month has been replaced by fibrous tissue. Its significance in fertility is direct: an embryo cannot implant into scar.

It follows injury to the basal layer of the endometrium, and the injuries are mostly medical rather than accidental. Surgical evacuation of the uterus after miscarriage or delivery, particularly when performed on an infected or recently pregnant uterus, is the commonest antecedent. Repeat procedures raise the risk further. Less often it follows myomectomy, caesarean section, or genital tuberculosis in regions where that is prevalent.

The presentation is characteristic once it is thought of: periods that become much lighter or stop altogether after a uterine procedure, sometimes with cyclical pain as menstrual blood is trapped behind an obstruction, and difficulty conceiving or recurrent miscarriage. The combination of a uterine procedure followed by a marked change in periods is the pattern that should prompt investigation.

Diagnosis is by hysteroscopy, which is also the treatment: the adhesions are divided under direct vision. What follows the surgery matters as much as the surgery. Adhesions re-form readily, so a barrier or a period of oestrogen to regenerate the lining is commonly used, and a second-look hysteroscopy confirms the cavity has stayed open. The honest limit is this: dividing adhesions restores the cavity, but where the basal layer has been destroyed over a wide area the lining does not regrow, and no operation replaces it. Outcome depends on how much healthy endometrium survived, which is known only after the first operation.

Male factor in detail

Male-factor problems account for around half of infertility, and the investigation stops short far more often than the female one does. An abnormal semen analysis is a finding, not a diagnosis; what follows should be an examination, a hormone profile and, in the right circumstances, genetic testing.

Azoospermia: no sperm in the ejaculate

Azoospermia is the complete absence of sperm in the ejaculate, found in a small percentage of men and a larger share of those attending fertility clinics. It is confirmed on a second sample examined after centrifugation, because a few sperm in a pellet changes the diagnosis entirely. The distinction that governs everything afterwards is between two types.

Obstructive azoospermia means production is normal but the path out is blocked — after vasectomy, from absence of the vas deferens associated with cystic fibrosis gene mutations, after infection, or after hernia or scrotal surgery. Testes are of normal size and FSH is normal. Sperm can almost always be retrieved surgically, and in some cases the obstruction itself can be reversed.

Non-obstructive azoospermia means production itself has failed or is severely reduced — genetic causes including Klinefelter syndrome and Y-chromosome microdeletions, previous chemotherapy or radiotherapy, undescended testes, or an unknown cause. Testes are often small and FSH raised. Here sperm retrieval succeeds in some men and not others, and no test predicts it reliably in advance.

That last sentence is the honest core of this section. Men with non-obstructive azoospermia are frequently told either that nothing can be done, which is wrong, or that retrieval will work, which cannot be promised. Genetic testing before retrieval is standard, both because it informs the chance of success and because some findings — a Y-chromosome deletion in particular — are passed to a son conceived with the retrieved sperm, and that belongs in the conversation before treatment rather than after.

TESE, micro-TESE and testicular sperm extraction

Testicular sperm extraction retrieves sperm directly from the testis for use in ICSI when there is none in the ejaculate. Conventional TESE takes tissue samples from the testis; micro-TESE uses an operating microscope to examine the seminiferous tubules and select the wider, more opaque ones most likely to contain sperm, removing far less tissue in the process.

Which is used depends on the diagnosis above. In obstructive azoospermia, where production is normal, simple aspiration or conventional extraction succeeds readily and micro-TESE is unnecessary. In non-obstructive azoospermia, where production is patchy and focal, micro-TESE is the technique with the higher retrieval rate and the lower cost in testicular tissue — and the difference between the two approaches is greatest exactly where the odds are worst.

Two practical points. Retrieval can be synchronised with the female partner’s egg collection, or performed beforehand and the sperm frozen; freezing first avoids the situation in which eggs are collected and no sperm is found, and many units prefer it for that reason. And the procedure is not without cost to the testis — it can affect testosterone production, which is monitored afterwards.

Varicocele

A varicocele is a dilated network of veins draining the testis, palpable as a bag of worms above the testicle and more common on the left for anatomical reasons. It is common in the general male population and considerably more common among men with abnormal semen parameters. It is thought to impair sperm production by raising scrotal temperature and by oxidative stress.

The honest position is that not every varicocele needs treating and the evidence has been argued over for decades. Repair is generally considered where three things coincide: the varicocele is palpable rather than visible only on ultrasound; the semen analysis is abnormal; and the female partner has no significant untreated factor of her own. Where it is repaired in that group, semen parameters improve in a meaningful proportion of men, and DNA fragmentation often falls. Improvement takes months, because a cycle of sperm production takes about three.

What repair does not do is guarantee conception, and a varicocele found incidentally in a man with a normal analysis is not a reason to operate. Repair is done by microsurgical subinguinal ligation, laparoscopically, or by radiological embolisation, and the choice is a matter of the operator’s experience and the anatomy.

Sperm freezing

Sperm freezing is the simplest and most reliable form of fertility preservation there is, and it is under-used. Sperm survives freezing well, keeps indefinitely in storage, and the process requires nothing more than producing a sample.

The situations where it should be offered are clear: before chemotherapy, radiotherapy or any treatment likely to damage fertility; before surgery on the testes or the genital tract; before gender-affirming hormone treatment; where the count is falling on serial analyses; and before a vasectomy. It is also used to bank surgically retrieved sperm, and to have a backup sample available for the day of egg collection — the day on which producing a sample to order is hardest, and on which failure has the highest cost.

Ovulation induction

Ovulation induction is treatment given to a woman who is not ovulating reliably, to make her ovulate. That is its whole purpose, and stating it plainly matters because it is frequently confused with the very different practice of stimulating a woman who already ovulates in the hope of producing more eggs.

The main indication is polycystic ovary syndrome, which is the commonest cause of absent or irregular ovulation. Before it starts, other causes of anovulation are excluded — thyroid disease, raised prolactin, low body weight and excessive exercise among them — because treating those directly is more effective than overriding them.

Two oral medicines dominate. Letrozole is an aromatase inhibitor that lowers oestrogen briefly, prompting the pituitary to drive follicle development; in polycystic ovary syndrome it produces higher ovulation and live birth rates than the older alternative and has become first line in most guidelines. Clomid — clomifene citrate — blocks oestrogen receptors at the pituitary to the same end; it works, and its recognised drawback is an anti-oestrogenic effect on cervical mucus and on the endometrium in some women. Injectable gonadotropins are used where the tablets fail, with closer monitoring, because they carry a higher risk of multiple follicles and of the response described under OHSS.

Which medicine, at what dose, for how many cycles and when to stop are decisions for the doctor prescribing them, made against ultrasound monitoring of the response. What is not a matter of preference is the monitoring itself: unmonitored ovulation induction is how multiple pregnancies happen, and a multiple pregnancy is the most common serious complication of fertility treatment.

Clomid and letrozole: how the two tablets differ

Both make an anovulatory woman ovulate, by different routes. Clomid — clomifene citrate — blocks oestrogen receptors at the pituitary, which reads the apparent shortage as a signal to drive follicle development. Letrozole is an aromatase inhibitor: it lowers oestrogen production briefly, producing the same signal without occupying the receptors. That difference is why letrozole avoids clomifene’s anti-oestrogenic effect on cervical mucus and on the endometrium, and it is the main reason most guidelines now place it first in polycystic ovary syndrome.

Neither is a fertility booster for a woman who already ovulates, and taking either without monitoring is how multiple pregnancies happen. Which one, at what dose, for how many cycles, and when to stop and move on are decisions made by the prescribing doctor against ultrasound tracking of the response.

PCOS and fertility

Polycystic ovary syndrome affects fertility mainly through anovulation, and the good news within it is that the ovaries usually contain plenty of eggs — the problem is releasing one, not having one. Treatment therefore succeeds often.

Three things change the odds and the first is unpopular but real: weight, where it is raised, because a modest reduction restores ovulation in a meaningful proportion of women and improves the response to every subsequent treatment. Insulin resistance is commonly present and is managed with the medical team. And the ovaries in PCOS respond briskly to stimulation, which cuts both ways — good egg numbers in an IVF cycle, and the highest risk of OHSS of any group, which is why protocols are deliberately gentler and why a freeze-all approach is often chosen. PCOS as a whole condition, beyond fertility, is managed with endocrinology and gynecology.

IUI: intrauterine insemination

IUI, or intrauterine insemination, places prepared sperm directly into the uterine cavity around the time of ovulation, using a fine catheter. The preparation is the part that does the work: the sample is washed and the most motile sperm concentrated into a small volume, bypassing the cervix and shortening the journey.

It is a modest intervention with a modest effect, and it suits a specific group: mild male-factor problems, unexplained infertility, ovulation disorders being treated with induction, cervical factors, and situations where intercourse is not possible. Two conditions have to be met for it to make any sense at all — at least one open fallopian tube, and enough motile sperm after preparation. Where the tubes are blocked or the count after washing is very low, IUI cannot work and offering it wastes the one thing that cannot be recovered, which is time.

Per-cycle success is considerably lower than IVF, and the cumulative benefit is concentrated in the first three or four attempts; beyond that the curve flattens and continuing usually means postponing a decision rather than making one. It is commonly combined with ovulation induction, which raises the rate and simultaneously raises the risk of a multiple pregnancy — the reason cycles are monitored and cancelled when too many follicles develop. A cancelled cycle is a functioning safety system, not a wasted one.

The choice between IUI and IVF turns mainly on age, on how long the couple have been trying, and on the semen parameters. For a younger couple with unexplained infertility, a short course of IUI before IVF is reasonable. Where the female partner is older, where reserve is reduced, where tubes are damaged or where the male factor is significant, going through IUI first is a delay dressed as a step.

IVF: in vitro fertilization, step by step

IVF — in vitro fertilization — means fertilisation outside the body: eggs are collected from the ovaries, combined with sperm in the laboratory, and the resulting embryo is transferred into the uterus. Everything else is detail, but the detail is where the differences between clinics live.

The IVF process follows the same five stages everywhere. Understanding them in order removes most of the confusion, because almost every question people ask is really a question about which stage they are in.

The IVF process and IVF timeline: how long each stage takes

The IVF process is easier to hold in mind as a timeline than as a list, because almost every question people ask is really a question about which stage they are in and how long it lasts. The IVF timeline from the first injection to the pregnancy test runs about four to six weeks, and it breaks down like this.

• Preparation, several weeks before. Investigations completed, consent taken, and often a pill or an injection to schedule the cycle so that it starts on a planned date — the step that makes an international cycle possible at all.
• Stimulation, roughly ten to fourteen days. Daily injections with scans and blood tests every few days. The length is set by how the follicles respond, not by the calendar, so the collection date firms up only partway through.
• Trigger, then thirty-four to thirty-six hours. A single injection at a specified hour, and collection a fixed interval later. This is the only immovable appointment in the whole cycle.
• Egg collection, one morning. Sedation, no incision, home the same day.
• Fertilisation and culture, five to six days. Fertilisation is confirmed the next morning; the embryos are then cultured to blastocyst while the laboratory reports progress.
• Transfer, minutes. Or freezing, if the plan is a frozen transfer in a later cycle.
• The two week wait, about a fortnight, ending with a blood test.

Where embryos are frozen — for genetic testing, for OHSS risk, or by design — the transfer moves to a subsequent cycle, which lengthens the calendar without adding to the stimulation. The stages themselves are described in order below.

Stage one: stimulation

Normally one follicle matures each month and the rest are lost. Stimulation uses injected gonadotropins to bring a cohort of follicles along together, so that several mature eggs are available rather than one. It runs for somewhere around a week and a half to two weeks, with the exact length set by the response rather than the calendar.

Alongside the stimulating drugs, a second medicine prevents the body releasing the eggs before they can be collected — either an antagonist started partway through the cycle, or an agonist begun earlier in a longer protocol. Which protocol is chosen follows from ovarian reserve, previous response and the risk of over-response, and it is one of the genuine areas of clinical judgement in this field.

Monitoring is by ultrasound and blood oestradiol every few days, tracking follicle number and size. The point of monitoring is to answer three questions repeatedly: is the response adequate, is it excessive, and when should the final maturation be triggered.

Stage two: the trigger shot

The trigger shot is a single injection that completes the final maturation of the eggs, given when enough follicles have reached the target size. Its timing is the most precisely scheduled event in the whole cycle: egg collection takes place a fixed interval afterwards, around thirty-four to thirty-six hours, because before that the eggs are not ready and after it the ovaries release them.

Two kinds are used and the difference matters for safety. Human chorionic gonadotropin mimics the natural surge and stays active for days, which is what makes it the main driver of OHSS in a woman who has over-responded. A GnRH agonist trigger produces a shorter surge and largely removes that risk, but it does not support the luteal phase afterwards, so it is used with a freeze-all approach or with additional support. Where a woman has responded briskly, switching the trigger is the single most effective step available for preventing severe OHSS.

Getting the timing of this injection right is the one part of the process that sits entirely with the patient. It is given at a specified hour, often late at night, and a missed or mistimed trigger can end a cycle that has otherwise gone perfectly.

Stage three: egg retrieval

Egg retrieval is done under sedation, transvaginally, with a fine needle guided by ultrasound through the vaginal wall into each follicle; the fluid is aspirated and passed to the laboratory, which identifies the eggs under the microscope. It takes a short time and there is no incision. Most people go home the same day with cramping and a bloated feeling for a day or two.

Not every follicle contains an egg, and not every egg collected is mature. This is the first point at which expectations meet biology, and it is worth being ready for it: the number of follicles seen on the scan is always higher than the number of eggs collected, which is higher than the number that are mature, which is higher than the number that fertilise, which is higher than the number that become usable embryos. That funnel is normal. It is also why the number of eggs collected, taken alone, tells you very little.

Stage four: fertilisation and ICSI

In conventional IVF the eggs and prepared sperm are placed together and fertilisation happens by itself. In ICSI — intracytoplasmic sperm injection — a single sperm is selected and injected directly into each mature egg.

ICSI was developed for male-factor infertility and that remains its clear indication: low count, poor motility, poor morphology, surgically retrieved sperm, or previous failure of conventional fertilisation. In those situations it transformed what was possible. Where it is not indicated, it has not been shown to improve results, and using it universally is a widespread practice that the evidence does not support — a clinic that performs ICSI on every case regardless of the semen analysis should be asked why.

Fertilisation is checked the following morning. Normal fertilisation shows two pronuclei; eggs that show none, or an abnormal number, are not used. A proportion of mature eggs fail to fertilise even with ICSI, and total fertilisation failure, though uncommon, does happen and is one of the situations where the laboratory has told the couple something no previous test could.

Stage five: embryo culture, blastocyst and embryo grading

Fertilised eggs are cultured for several days. A blastocyst is the stage reached around day five or six, when the embryo has organised itself into an outer layer that will become the placenta, an inner cell mass that will become the fetus, and a fluid-filled cavity. Culturing to blastocyst rather than transferring on day three allows the embryos that were never going to continue to declare themselves in the laboratory rather than in the uterus, which is why blastocyst transfer has become standard where there are enough embryos to make the selection meaningful.

Embryo grading describes appearance: the degree of expansion of the blastocyst, and the quality of the inner cell mass and outer layer, usually written as a number and two letters. Time-lapse imaging adds the pattern and timing of the divisions, observed without removing the embryo from the incubator.

Grading deserves a plain caveat, because couples read these letters as a score of their future child. It is a morphological assessment that ranks embryos in a batch by their likelihood of implanting. It is not a measure of chromosomal normality, it is not a measure of the health of a resulting baby, and lower-graded embryos produce healthy pregnancies routinely. Its honest use is ordering the queue for transfer, and nothing more.

Embryo transfer

Embryo transfer is the shortest and least dramatic step in the whole cycle, which surprises people who have braced for it. A fine catheter is passed through the cervix under ultrasound guidance and the embryo is deposited in the uterine cavity. It takes minutes, needs no anaesthetic and feels like a smear test. Nothing about lying still afterwards, or bed rest, or avoiding stairs, improves the outcome — the embryo cannot fall out, and studies of bed rest after transfer have consistently found no benefit and sometimes the opposite.

The decision that does matter is how many embryos to transfer, and the answer in modern practice is almost always one. Transferring two raises the chance of a pregnancy modestly and the chance of a twin pregnancy enormously, and a twin pregnancy is the most common serious complication of IVF — higher rates of prematurity, growth restriction, pre-eclampsia and neonatal intensive care. Single embryo transfer with the remaining embryos frozen achieves a similar cumulative chance of a baby across the whole treatment, without concentrating the risk into one pregnancy. Where a clinic offers to transfer more, the reason should be specific to the individual rather than a general policy.

Luteal phase support — progesterone, given by one route or another — continues after the transfer, because the medicines used in stimulation disturb the body’s own production. Which preparation, which route and for how long are prescribing decisions made by the treating team.

The two week wait

The two week wait is the interval between transfer and the pregnancy test, and by common consent it is the hardest part of treatment. It is worth saying two things about it plainly.

First, symptoms during it are uninterpretable. Cramping, breast tenderness, fatigue, spotting and their complete absence are all consistent with pregnancy and with its absence, and progesterone support produces most of them regardless. People spend this fortnight reading their bodies for a signal that is not there. Second, home urine tests taken early mislead in both directions — a trigger injection containing hCG can still be detectable and produce a false positive, and a real pregnancy can be too early to register. The blood test for beta-hCG on the scheduled day is the answer, and testing before it generally adds distress rather than information.

Frozen embryo transfer

Frozen embryo transfer uses an embryo frozen in a previous cycle and thawed for transfer. The technique that changed it was vitrification — ultra-rapid freezing that prevents ice crystals forming — after which survival rates rose to the point where a frozen embryo is no longer a lesser option than a fresh one.

That shift has consequences beyond convenience. In a fresh cycle the uterus has just been through stimulation, with oestrogen levels far above natural and an endometrium altered accordingly. A frozen transfer happens in a quieter cycle, which is why fresh vs frozen embryo transfer is now a genuine clinical question rather than a matter of logistics. Freezing everything and transferring later is standard where there is any OHSS risk, where progesterone has risen prematurely, where genetic testing results are awaited, and where the endometrium is not ready.

The transfer itself can be prepared two ways: a medicated cycle, where oestrogen and progesterone build and time the lining, giving precise scheduling; or a natural cycle, tracking the woman’s own ovulation, which requires fewer drugs and less flexibility over dates. For international patients the medicated route is often chosen for the scheduling alone, and that is a legitimate reason.

Embryo freezing and storage

Embryo freezing is what makes single embryo transfer sensible: surplus good-quality embryos are vitrified after the fresh cycle, and each subsequent transfer needs no further stimulation or egg collection. Embryos do not deteriorate measurably with time in storage, and the practical limits are the storage period permitted by the law of the country where they are kept and the consent of both partners, which can be withdrawn.

Those two constraints deserve attention before treatment rather than after, and they differ sharply between countries. Anyone freezing embryos abroad should establish in writing how long they will be stored, what it costs to keep them, what happens if the storage fee lapses, whether they can be transported to another country, and what the position is if the couple separate — this last is the one that causes the most grief and is discussed the least.

OHSS: ovarian hyperstimulation syndrome

OHSS — ovarian hyperstimulation syndrome — is the most important complication of fertility treatment, and it is the one that has genuinely changed in the past decade: modern protocols have made severe cases considerably less common than they were.

The mechanism explains everything about it. Ovaries that have responded excessively release vasoactive substances that make blood vessels leak; fluid moves out of the circulation into the abdomen and sometimes the chest. The result is enlarged ovaries, a swollen abdomen, a falling circulating volume and thickened blood. Symptoms are bloating, abdominal pain, nausea, rapid weight gain and reduced urine output; in severe cases, breathlessness and the risk of clots.

Who is at risk is well characterised: polycystic ovary syndrome, high AMH and antral follicle count, younger age, a previous episode, and a large number of follicles in the current cycle. What matters is that these are all known before the trigger, which is why prevention is possible rather than theoretical. The measures are: gentler stimulation in high responders, an antagonist protocol, switching the trigger from hCG to a GnRH agonist as described under the trigger shot, freezing all embryos rather than transferring fresh — a pregnancy prolongs and worsens OHSS — and cancelling a cycle that has gone too far.

A cycle cancelled, or converted to freeze-all, for this reason is a unit doing its job. It is also, understandably, devastating for a couple who have travelled and paid, which is precisely why the possibility should be discussed before the cycle starts rather than presented as an unlucky surprise.

Genetic testing of embryos: PGT-A and PGD

Testing embryos before transfer means taking a small biopsy of cells from the outer layer of a blastocyst and analysing them. The embryo is frozen while the result is awaited, which is why genetic testing and frozen transfer travel together.

PGT-A: testing for chromosome number

PGT-A screens embryos for aneuploidy — the wrong number of chromosomes — which is the commonest reason an embryo fails to implant or a pregnancy miscarries, and whose frequency rises steeply with the age of the egg. The rationale is to transfer the embryos most likely to succeed first, shortening the path to a pregnancy.

The honest account includes the debate. PGT-A reduces the miscarriage rate and the number of failed transfers, and it improves the chance of success per transfer. What it has not consistently shown, across the whole population, is an increase in the chance of a baby per cycle started — because it selects among the embryos already present rather than creating better ones, and in women with few embryos it can leave nothing to transfer. There is also the mosaic result, where a biopsy shows a mixture of normal and abnormal cells: some such embryos produce healthy babies, and the counselling around them is genuinely difficult. A clinic that recommends it for every patient without reference to age or embryo number is over-selling it; a clinic that never discusses it in a woman over thirty-eight with several blastocysts is under-serving her.

PGD: testing for a specific inherited condition

PGD — preimplantation genetic diagnosis, now often called PGT-M — is a different procedure with a different purpose. It tests embryos for one specific inherited condition known to run in the family, so that an embryo unaffected by it can be transferred. It is used where a couple carry a single-gene disorder such as cystic fibrosis, thalassaemia, sickle cell disease, Huntington’s disease or a BRCA mutation, or where one partner carries a chromosomal rearrangement.

It requires preparation. The specific mutation has to be identified in the family first, and a test built for it, which takes time before any cycle begins. Genetic counselling is part of the process rather than an add-on. This is also the one context in which the sex of an embryo may lawfully be selected in Turkey — where the condition being avoided is sex-linked — and that exception is described under what Turkish law permits.

IVF success rates: what the numbers do and do not say

This page does not quote an IVF success rate, and the reason is not evasion. It is that a single percentage is the most misleading number in fertility medicine, and comparing two clinics by it is how people choose badly.

Four things have to be fixed before any figure means anything. The denominator: per cycle started, per egg collection, per embryo transfer or per patient — the same clinic and the same patients produce very different numbers depending which is used, and per-transfer figures are the most flattering because they exclude everyone whose cycle never reached a transfer. The numerator: a positive test, a pregnancy on a scan, or a baby taken home. Only the last matters, and it is the lowest. Age: ordinary averages across all ages are meaningless for any individual, and the age bands a clinic chooses to publish can flatter it. Case mix: a clinic that declines difficult cases reports better figures than one that accepts them, without being better.

What is worth asking instead: the cumulative chance of a live birth per egg collection including all frozen transfers from it, in your age band, with your diagnosis. That is one number that answers the real question — what happens to people like me — and a unit that can produce it is a unit that measures itself honestly.

And one thing has to be said plainly, because avoiding it is the commonest form of dishonesty in this field. Success falls steeply with the age of the eggs, and it falls fastest after the late thirties. Not gradually, and not in a way that better technology has changed — the limiting factor is the proportion of eggs carrying the right number of chromosomes, and no protocol, supplement, laboratory or clinic alters it. By the mid-forties, with a woman’s own eggs, the chance per cycle is very low. Anyone quoting reassuring figures to a woman in that position without naming the denominator, or quoting rates that in fact come from donor eggs, is selling something. Hearing the real position is unwelcome; being allowed to spend two years and a great deal of money discovering it is worse.

Is there an IVF age limit, and does IVF over 40 work?

Two different limits are involved and they are often conflated. There is a legal or regulatory limit, which differs by country and by funding source, and there is a clinical one, which is a judgement about whether treatment can reasonably be expected to work.

The clinical judgement rests on the ovarian reserve tests described under ovarian reserve and, dominantly, on age itself. There comes a point at which the chance with a woman’s own eggs is low enough that a unit will say so rather than sell another cycle, and being told that is a mark of a responsible clinic rather than an unkind one. Where a woman is close to that boundary, the options that remain narrow to a small list, and in Turkey one of the usual items on that list is not legally available — see what Turkish law permits. IVF over 40 with a woman’s own eggs is entirely reasonable to attempt with realistic expectations; the mistake is attempting it with expectations set by figures drawn from younger patients.

Recurrent implantation failure, the endometrium and the ERA test

Recurrent implantation failure describes repeated transfers of good-quality embryos that do not result in a pregnancy. It is a description rather than a diagnosis, and it is the area of fertility medicine with the widest gap between what is sold and what is proven — which makes it the area where patients are most exposed.

The investigations with a solid basis look for structural and systemic causes: the uterine cavity by hysteroscopy, an untreated hydrosalpinx, adhesions, submucosal fibroids, thyroid function, and a thorough re-examination of embryo quality and of the laboratory conditions themselves. Endometrial thickness is measured before transfer because a very thin lining is associated with lower success — though the association is weaker than the attention it receives, and a great many pregnancies occur at thicknesses that would worry someone reading about it online.

The ERA test — endometrial receptivity analysis — biopsies the lining to determine whether the window of implantation falls at the expected time, so transfer can be shifted. It is offered widely. The evidence supporting it is weaker than its marketing, and randomised data have not shown a consistent benefit in unselected patients. It may have a place after several failures with good embryos; it is not a routine test, and it should not be presented as one.

The same caution applies with more force to the immune treatments that circulate in this space — intralipid infusions, steroids, immunoglobulin, blood-thinning regimens given without a diagnosed clotting disorder. They are frequently offered to couples who have run out of conventional options and are, by that stage, willing to try anything. Most are unproven for this indication, some carry real risk, and any of them should be prescribed for a named diagnosis by the doctor responsible, not added to a package because a cycle has failed.

Recurrent miscarriage

Recurrent miscarriage — commonly defined as two or more consecutive pregnancy losses — is investigated because a proportion of cases have a treatable cause, and because the investigation itself, even when it finds nothing, changes what happens next.

The recognised causes are a short list. Antiphospholipid syndrome, which is the most important because it is treatable and is found by a blood test. A chromosomal rearrangement in one partner, found by karyotyping. Uterine abnormalities — a septum, submucosal fibroids, adhesions. Thyroid disease and poorly controlled diabetes. And, overwhelmingly the commonest single explanation, chromosomal abnormality in the embryo itself, which rises with the age of the egg and is a matter of chance rather than of anything either partner did.

The honest summary is that no cause is identified in around half of couples, and that this group has a better outlook than the numbers feel like they should — the majority go on to a successful pregnancy without specific treatment. Supportive early pregnancy care has a measurable effect in this situation, and it is one of the few places in medicine where reassurance is itself an intervention. What does not help is the accumulation of unproven treatments, and couples in this position are offered them constantly. Ongoing care is shared with obstetrics.

Fertility preservation and egg freezing

Fertility preservation means storing eggs, sperm, embryos or tissue for use later. It divides into two situations that share a technique and share almost nothing else.

Medical preservation is done before treatment that will damage fertility — chemotherapy, radiotherapy, surgery on the ovaries or testes, or gender-affirming hormone treatment. Here the priority is speed, because the treatment cannot wait long, and the co-ordination with the treating oncologist is the whole job. Sperm freezing is immediate. For women, a stimulation cycle can now usually be started at any point in the cycle rather than waiting for the next one, which has removed most of the delay that used to make this impossible. Ovarian tissue freezing is an option where there is no time at all, or before puberty. This work is done alongside medical oncology.

Elective egg freezing is done to postpone the decision rather than the biology. Egg freezing works — vitrified eggs survive thawing well and produce pregnancies — but three facts belong in the decision and are frequently soft-pedalled. The age at freezing is what determines the value of the eggs, so freezing at thirty-two and freezing at thirty-nine buy very different things. A meaningful number of eggs is needed, because of the funnel described under egg retrieval — not every egg survives thawing, fertilises and becomes a usable embryo — and that often means more than one collection cycle. And it is insurance, not a guarantee: a proportion of women who freeze eggs never use them, and of those who do, some do not have a baby from them.

IVF twins and multiple pregnancy

IVF twins are often the outcome couples secretly hope for — one treatment, two children, the family complete. It is worth being blunt about why fertility medicine has spent twenty years trying to prevent exactly that.

A twin pregnancy is a higher-risk pregnancy for the mother and substantially higher-risk for the babies: preterm birth is the norm rather than the exception, with the associated risks of low birth weight, neonatal intensive care and the long-term consequences of prematurity. Rates of pre-eclampsia, gestational diabetes, haemorrhage and caesarean delivery all rise. None of this makes twins a bad outcome once they exist — it makes deliberately arranging a high chance of them a poor clinical decision when a similar cumulative chance of a baby is available without it.

That is why single embryo transfer is standard, and why ovulation induction and IUI are monitored and cancelled when too many follicles develop. Identical twins can still occur from a single transferred embryo, at a slightly raised rate after IVF, and that is not preventable. What is preventable is the version that comes from transferring two.

What Turkish law permits — and what it does not

This is the section that matters most to anyone considering treatment in Turkey, and it is the one most often missing from pages about it. Assisted reproduction is regulated differently in every country, and the differences are not administrative details — they determine whether the treatment someone is travelling for can legally happen at all.

Turkish regulation permits assisted reproduction only for legally married couples, using the couple’s own eggs and sperm. The consequences follow directly:

• Egg donation is not permitted. A woman who needs donor eggs — because of premature ovarian insufficiency, after cancer treatment, or because her own eggs are no longer viable — cannot be treated with them in Turkey.
• Sperm donation is not permitted, which includes severe male factor where no sperm can be retrieved, and single women and same-sex couples seeking donor sperm.
• Donor embryos and surrogacy are not permitted.
• Sex selection is not permitted for family balancing or preference. The single exception is medical: where a serious sex-linked genetic condition is being avoided, embryo sex may be determined as part of PGD.

Two practical points follow. Anyone searching for donor-gamete treatment abroad and finding Turkish clinics near the top of the results should treat that as a reason to ask directly and get the answer in writing before booking anything — it is also why several other destinations dominate that particular search. And these rules are stated here as the legal framework rather than as a clinical position: the treatments exist and are entirely legitimate where they are lawful. What is not legitimate is allowing someone to travel for something that cannot be provided.

What Turkey does permit is the full range of treatment using a couple’s own gametes: IVF and ICSI, surgical sperm retrieval including micro-TESE, blastocyst culture, vitrification, frozen transfer, PGT-A and PGD, and fertility preservation. For the large majority of couples that is precisely the treatment they need.

IVF cost: what drives it and what a quotation should cover

This page does not publish a figure for IVF cost, because a cycle is not one item and the number quoted in an advertisement is rarely the number paid. What follows is what actually varies, so that two quotations can be compared.

The largest single variable is medication, and it is the one most often excluded from a headline price. The dose of gonadotropin depends on ovarian reserve and body weight, and the difference between a low responder needing a high dose and a woman with high reserve needing a low one is substantial. A quotation that does not state whether drugs are included is not comparable to one that does.

The others: whether ICSI is included or added; whether embryo freezing and the first year of storage are included, and what storage costs thereafter; whether genetic testing is included, and priced per embryo or per cycle; how many monitoring scans and blood tests are covered; whether a frozen transfer from the same collection is included or charged separately — which matters more than anything else, because the cumulative chance of a baby depends on those transfers; and what happens financially if a cycle is cancelled before egg collection, or if no eggs or no embryos are obtained.

That last item is the one to ask about first. Cycles are cancelled, and cycles that reach collection sometimes produce nothing usable. A provider with a clear written position on it is quoting for a course of treatment; a provider that has not addressed it is quoting for the best case.

IVF abroad and IVF Turkey: what to check before travelling

Searches for IVF abroad outnumber searches for any single destination, and the reasons people travel are consistent: cost, waiting lists at home, age limits imposed by a national funding system, or access to something not available locally. All are legitimate. What follows applies to any destination, and to IVF Turkey specifically where it differs.

Start with the question that decides whether the rest matters. Is the treatment you need legal where you are going? For IVF and ICSI with a couple’s own eggs and sperm, in Turkey, the answer is yes. For donor eggs, donor sperm or surrogacy the answer is no, and the section on what Turkish law permits sets out why. Getting this answered in writing before anything is booked prevents the single worst outcome in fertility travel, which is arriving for a treatment that cannot be given.

The rest are the checks that separate a clinical pathway from a package, wherever it is:

• Was there a real assessment, and could it have ended in advice against treatment? A clinic that accepts everyone, at any age, with any reserve, is not assessing.
• How much of the cycle happens at home and how much on site? Most monitoring scans and blood tests can be done locally and reported, which is what makes travelling feasible — the parts that must happen on site are egg collection and transfer. A pathway that requires the whole stimulation abroad is asking for weeks rather than days, and should say so before booking.
• Who supervises the monitoring done at home, and how are dose changes communicated? This is the practical weak point of every international cycle. It needs a named person and a defined channel, not an inbox.
• What is the position if the cycle is cancelled, or if OHSS develops after you fly home? OHSS can declare itself days after egg collection, and a woman who has flown home is then presenting to a hospital that did not treat her. She should leave with a written summary of the protocol, the drugs and the trigger used, for exactly this reason.
• Where will the embryos be stored, for how long, at what cost, and can they be moved? Embryos frozen abroad are subject to the law of that country, not of the patient’s own.
• What are the published outcomes, on which denominator, for which age band? See success rates — the denominator is the whole question.

Two further points. Flying itself does not reduce the chance of implantation, and the common advice to avoid travel immediately after a transfer has no good evidence behind it; the reason to stay is access to care if something goes wrong, not the flight. And the cost comparison people run in their heads is usually the cost of one cycle, when the number that matters is the cost of the whole course including the frozen transfers — which is where the real difference between quotations sits.

IVF Turkey cost: comparing the whole course, not one cycle

Cost is the commonest reason people search IVF Turkey cost, and most of the treatment offered to international patients is concentrated in Istanbul, which is why IVF Istanbul returns much the same clinics. The difference against private treatment in the United Kingdom, Ireland or the United States is real. What makes comparison difficult is not the currency but the scope, and the items set out under IVF cost apply here in full — medication above all, since it is the largest variable and the one most often excluded from a headline.

Two additions apply specifically when travelling. The monitoring done in your own country is usually charged by the clinic doing it, and belongs in the total even though it does not appear on the treating clinic’s quotation. And the number that actually matters is the cost per baby rather than per cycle — which means including the frozen transfers from the same collection, and the realistic possibility of a second cycle. A quotation covering one fresh cycle only is the cheapest way to present the most expensive route.

Your multidisciplinary team

Fertility treatment is delivered by a team in which the least visible member has the greatest influence on the result.

The reproductive endocrinologist investigates both partners, decides whether treatment is appropriate and which, designs the stimulation protocol and performs the egg collection and transfer. The embryologist — the member most patients never meet — handles the eggs, performs the ICSI, cultures the embryos, grades them and carries out the freezing and thawing. Laboratory quality is the single largest determinant of outcome that a patient cannot see from the outside, and it is why the laboratory is a fair thing to ask about. The andrologist or reproductive urologist investigates male factor and performs surgical sperm retrieval. The fertility nurse teaches the injections and is, in practice, the person a couple speaks to most. The genetic counsellor is involved wherever PGD or a known familial condition is in play. And psychological support is part of the treatment rather than an extra, because the demands of a cycle and of its failure are considerable and predictable.

Around them: gynecology and obstetrics for surgery on the uterus and for the pregnancy that follows, endocrinology for thyroid, prolactin and diabetes, urology for varicocele and reconstructive male surgery, and medical oncology where preservation is being arranged before cancer treatment.

The international patient journey

An IVF cycle for a patient travelling from abroad follows the same clinical sequence as for a local patient, split between what can be done at home and what cannot.

Records and remote review

Both partners’ results are reviewed before travel: AMH and antral follicle count, tubal assessment, any previous cycle summaries with protocols and outcomes, and a semen analysis. Previous cycle details matter more than anything else in the file — the protocol used, the dose, the number of eggs collected and the fertilisation rate say more than any test. The review establishes whether treatment is appropriate, which protocol is proposed, and what remains to be done.

Stimulation, monitored at home

Stimulation usually begins at home, with scans and blood tests done locally and reported to the treating team, and the dose adjusted remotely. This is what keeps the trip short, and it is also the part that depends entirely on the arrangement being properly organised: a named contact, an agreed schedule, and a local clinic willing to perform monitoring for a cycle it is not running.

Collection and transfer on site

Travel is timed to the trigger. Egg collection follows a fixed interval after it, fertilisation is checked the next morning, and the embryos are cultured while the couple remain in the city. A fresh transfer takes place a few days later; where the embryos are frozen instead — for OHSS risk, for genetic testing, or by plan — the transfer happens on a later visit, which is shorter.

Afterwards

The couple leave with the protocol, the drugs used, the laboratory report, the embryo details and the storage arrangements in writing, in a form another clinician can act on — this matters most if OHSS develops after the flight home. The pregnancy test is done at home on the scheduled day and reported back, and early pregnancy scans are arranged locally with the results reviewed by the treating team.